Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback